DPP4 and metabolic dysfunction-associated steatotic liver disease: Moreover, the studies either have only NAFLD patients as the target population or only evaluate the effect of SGLT-2 inhibitors, GLP-1RAs agonists and DPP-4 inhibitors on liver enzymes.